ClinicalTrials.gov
ClinicalTrials.gov Menu

The Benefits of Hemp Protein Supplementation During Resistance Training

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02529917
Recruitment Status : Completed
First Posted : August 20, 2015
Last Update Posted : May 5, 2017
Sponsor:
Information provided by (Responsible Party):
Phil Chilibeck, University of Saskatchewan

Brief Summary:
Forty physically active men and women aged 18-45y will take part in an 8-week resistance training program, randomized (double blind) 1:1 into each of two groups. Twenty participants will be randomized to receive 60 g/d of hemp powder (containing approximately 40 g protein and 9 g oil) supplementation and 20 randomized to receive 60 g/d of soy supplementation (matched to the hemp for macronutrients and calories) during eight weeks of training. Each participant will complete testing before and after the intervention for assessment of body composition (lean tissue, fat, and bone mass), strength, central fatigue, markers of inflammation, and bone resorption. Over the 8-weeks of training, participants will train four-five days per week for 1-1.5 hours per session with exercises targeting all major muscle groups. The training will involve a "two day split" where different muscle groups are trained on two consecutive days (day 1 involves chest, back, and arms; day 2 legs, shoulders, and abdominals). Resistance training will provide the necessary stimulus for protein synthesis to optimize the effect of a protein-containing nutritional supplement. The hemp or soy powder will be consumed in two doses (i.e. 30 g powder containing 20 g protein per dose) immediately after exercise sessions and one hour after exercise. This dosing regimen is optimal for stimulating muscle protein synthesis and building muscle mass . On the one non-training day per week the two doses will be consumed with meals.

Condition or disease Intervention/treatment Phase
Sarcopenia Dietary Supplement: Hemp powder Dietary Supplement: Soy Powder Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: The Benefits of Hemp Protein Supplementation During Resistance Training
Study Start Date : August 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: Hemp powder
Hemp powder supplement
Dietary Supplement: Hemp powder
Hemp powder supplement

Active Comparator: Soy powder
Soy powder supplement
Dietary Supplement: Soy Powder
Soy powder supplement




Primary Outcome Measures :
  1. Change in lean tissue mass (kg) [ Time Frame: 8 weeks ]
    Lean tissue mass measured with dual energy x-ray absrorptiometry


Secondary Outcome Measures :
  1. Change in fat mass (kg) [ Time Frame: 8 weeks ]
    Fat mass as measured by dual energy x-ray absorptiometry

  2. Change in bone mass (grams) [ Time Frame: 8 weeks ]
    Bone mass as measured by dual energy x-ray absorptiometry

  3. Change in elbow flexor muscle thickness (cm) [ Time Frame: 8 weeks ]
    Muscle thickness as assessed by ultrasound

  4. Change in knee extensor muscle thickness (cm) [ Time Frame: 8 weeks ]
    muscle thickness as measured by ultrasound

  5. Change in bench press strength (kg) [ Time Frame: 8 weeks ]
    Bench press strength as assess on a plate-loaded machine by the 1-RM method

  6. Change in arm curl strength (kg) [ Time Frame: 8 weeks ]
    Arm curl strength as assessed with dumbbells by the 1-RM method

  7. Change in leg press strength (kg) [ Time Frame: 8 weeks ]
    Leg press strength as assessed on a leg-press machine by the 1-RM method

  8. Change in inflammation by interleukin-6 (mmol/l) levels [ Time Frame: 8 weeks ]
    Interleukin-6 levels measured from saliva samples

  9. Change in inflammation by C-reactive protein (mmol/l) levels [ Time Frame: 8 weeks ]
    C-reactive protein levels measured from saliva samples

  10. Change in bone resorption (N-telopeptides) (mmol/l) [ Time Frame: 8 weeks ]
    N-telopeptides measured from urine samples

  11. Change in voluntary muscle activation (Nm) [ Time Frame: 8 weeks ]
    Voluntary muscle activation as measured by the interpolated twitch technique



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • At least 6 months experience with resistance training

Exclusion Criteria:

  • Allergies to hemp or soy
  • Consumption of other nutritional supplements in previous month
  • Answered "yes" to questions on the Physical Activity Readiness Questionnaire

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02529917


Locations
Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 5B2
Sponsors and Collaborators
University of Saskatchewan
Investigators
Principal Investigator: Philip Chilibeck University of Saskatchewan

Responsible Party: Phil Chilibeck, Ph.D., University of Saskatchewan
ClinicalTrials.gov Identifier: NCT02529917     History of Changes
Other Study ID Numbers: 15-95
First Posted: August 20, 2015    Key Record Dates
Last Update Posted: May 5, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical
Signs and Symptoms